Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by wobbleson Dec 23, 2020 2:40pm
228 Views
Post# 32171004

RE:Soon

RE:SoonI too was in ACST and expected good things. I ignored my gut feeling of impending doom on a couple of occasions (I normally trust my gut, and I couldn't shake the constant feeling I was on shaky ground when I ignored it on several occasions, the first time back in December, 2019). I did then, and do now, have a very strong lack of respect for Acasti Pharma leaders.
I got out in June completely. Once in a while I look at ACST. To me, it's just an abstract gambling instrument now, with no integral connnection to a good product or good prospects. Just a plaything for the profits generated from volatility. I don't roll that way, so have zero interest in grovelling for money with something I have no respect for.

I got into ATE around the same time. Like ACST, I bought it (and kept adding) because, among other reasons but still a strong overriding one -- a belief in the benefit to humans that will result. That's where the similarity ends between Acasti and Antibe, though. Although I am neutral about Dan Legault as CEO (neither rah-rah nor putting him down excessively), I'm also aware of my lack of insight and experience in biotech/pharma investing, and I get a lot of good information here from some smart, experienced folks who do a lot of hard work in digging out and sharing.

As you say, this is a really solid suite of products with groundbreaking technology in the hydrogen sulfide based delivery system. I'm very happy to wait on ATE (good rhyme). Success here will make me feel very good indeed not only for my own fortunes, but for the great step forward in the management of chronic pain. Everybody knows at least one person who would benefit immensely.

Sorry for killing so many electrons with my long missive, but I couldn't stop.
Cheers!
<< Previous
Bullboard Posts
Next >>